Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.22 USD
+0.03 (2.52%)
Updated Jun 7, 2024 04:00 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Brokerage Reports
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 1 - 20 ( 273 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: Focus Remains on Advancing the Ph2b ODYSSEY Trial Toward a Q3 Readout
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Wet AMD Trial Completes Randomization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q3:23 Financials; Ph2b ODYSSEY Trial Underway for CLS-AX/wAMD, Readout in Q3:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
New License Deal; Positive Clinical Update From Partner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Wet AMD Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Phase 2b Trial Enrollment Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q2: On-Track for a Topline Ph2b ODYSSEY Readout for CLSAX/ wAMD in Q3:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Patient Enrollment and Dosing Underway in Phase 2b Wet AMD Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE New Drug Application Accepted in Australia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b ODYSSEY Trial Commences Patient Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y